151 related articles for article (PubMed ID: 8018663)
1. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
Falcon CR; Cattaneo M; Panzeri D; Martinelli I; Mannucci PM
Arterioscler Thromb; 1994 Jul; 14(7):1080-3. PubMed ID: 8018663
[TBL] [Abstract][Full Text] [Related]
2. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.
Langman LJ; Ray JG; Evrovski J; Yeo E; Cole DE
Arch Intern Med; 2000 Apr; 160(7):961-4. PubMed ID: 10761961
[TBL] [Abstract][Full Text] [Related]
3. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives.
Beaumont V; Malinow MR; Sexton G; Wilson D; Lemort N; Upson B; Beaumont JL
Atherosclerosis; 1992 Jun; 94(2-3):147-52. PubMed ID: 1632868
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
7. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
[TBL] [Abstract][Full Text] [Related]
8. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.
Manns BJ; Burgess ED; Hyndman ME; Parsons HG; Schaefer JP; Scott-Douglas NW
Am J Kidney Dis; 1999 Oct; 34(4):669-77. PubMed ID: 10516348
[TBL] [Abstract][Full Text] [Related]
9. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia.
Kang SS; Wong PW
Atherosclerosis; 1996 Jan; 119(2):135-8. PubMed ID: 8808490
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
[TBL] [Abstract][Full Text] [Related]
11. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.
Ridker PM; Hennekens CH; Selhub J; Miletich JP; Malinow MR; Stampfer MJ
Circulation; 1997 Apr; 95(7):1777-82. PubMed ID: 9107163
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocyst(e)inemia in chronic stable renal transplant patients.
Machado DJ; Paula FJ; Sabbaga E; Ianhez LE
Rev Hosp Clin Fac Med Sao Paulo; 2000; 55(5):161-8. PubMed ID: 11175576
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocyst(e)inemia and risk of ischemic stroke among young Asian adults.
Tan NC; Venketasubramanian N; Saw SM; Tjia HT
Stroke; 2002 Aug; 33(8):1956-62. PubMed ID: 12154245
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
15. Causes and consequences of hyperhomocyst(e)inemia.
Pietrzik K; Brönstrup A
Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483
[TBL] [Abstract][Full Text] [Related]
16. Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome.
Joven J; Arcelús R; Camps J; Ordóñez-Llanos J; Vilella E; González-Sastre F; Blanco-Vaca F
J Mol Med (Berl); 2000; 78(3):147-54. PubMed ID: 10868477
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].
Sydow K; Böger RH
Z Kardiol; 2001 Jan; 90(1):1-11. PubMed ID: 11220081
[TBL] [Abstract][Full Text] [Related]
18. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease.
Stanger O; Weger M; Renner W; Konetschny R
Clin Chem Lab Med; 2001 Aug; 39(8):725-33. PubMed ID: 11592442
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease.
Genest JJ; McNamara JR; Upson B; Salem DN; Ordovas JM; Schaefer EJ; Malinow MR
Arterioscler Thromb; 1991; 11(5):1129-36. PubMed ID: 1911700
[TBL] [Abstract][Full Text] [Related]
20. Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans.
Yoo JH; Park JE; Hong KP; Lee SH; Kim DK; Lee WR; Park SC
Thromb Res; 1999 Apr; 94(1):45-52. PubMed ID: 10213180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
